Testing effectiveness (Phase 2)Study completedNCT03126019What this trial is testingINCB050465 in Relapsed or Refractory Follicular LymphomaWho this might be right forLymphoma Incyte Corporation 126
Testing effectiveness (Phase 2)Active Not RecruitingNCT04533581What this trial is testingStudy of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Who this might be right forIndolent B-cell Non-Hodgkin's Lymphoma Kyowa Kirin Co., Ltd. 61
Not applicableStudy completedNCT00521430What this trial is testingDonor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more Asan Medical Center 30
Early research (Phase 1)Looking for participantsNCT06547528What this trial is testingA Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLWho this might be right forRelapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ono Pharmaceutical Co., Ltd. 108
Early research (Phase 1)Study completedNCT00161187What this trial is testingIrradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid TumorWho this might be right forCancer University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)WithdrawnNCT01652014What this trial is testingSingle or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+51 more University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Ended earlyNCT00093704What this trial is testingBortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive LymphomaWho this might be right forLymphomaLymphoproliferative Disorder Jonsson Comprehensive Cancer Center 1
Early research (Phase 1)Active Not RecruitingNCT04447716What this trial is testingAn Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentWho this might be right forRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Indolent Adult Non-Hodgkin Lymphoma+5 more Thomas Jefferson University 4
Early research (Phase 1)Ended earlyNCT04045028What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forMultiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma Genentech, Inc. 41
Early research (Phase 1)Not Yet RecruitingNCT07335328What this trial is testingFully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell MalignanciesWho this might be right forB-cell Non Hodgkin Lymphoma Medical College of Wisconsin 24
Testing effectiveness (Phase 2)WithdrawnNCT00881387What this trial is testingRituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentWho this might be right forLymphoma University of Miami
Early research (Phase 1)UnknownNCT04712864What this trial is testingStudy of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaWho this might be right forT-Cell LymphomaPeripheral T-Cell Lymphoma RefractoryCutaneous T-Cell Lymphoma Refractory+2 more Legend Biotech USA Inc 50
Not applicableStudy completedNCT04213209What this trial is testingSpecial Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"Who this might be right forPeripheral T Cell LymphomaPediatric Hodgkin Lymphoma Takeda 95
Testing effectiveness (Phase 2)Study completedNCT01939899What this trial is testingPhase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular LymphomaWho this might be right forFollicular Lymphoma Millennium Pharmaceuticals, Inc. 29
Large-scale testing (Phase 3)Study completedNCT00782145What this trial is testingA Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their FamiliesWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+6 more Tufts Medical Center 198
Testing effectiveness (Phase 2)Study completedNCT00021372What this trial is testingPaclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forLymphoma Fox Chase Cancer Center 25
Early research (Phase 1)Active Not RecruitingNCT03962465What this trial is testingPhase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLWho this might be right forB-cell Acute Lymphoblastic Leukemia University of Virginia 36
Large-scale testing (Phase 3)Active Not RecruitingNCT04680052What this trial is testingAssess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.Who this might be right forFollicular LymphomaMarginal Zone Lymphoma Incyte Corporation 654
Testing effectiveness (Phase 2)Ended earlyNCT00265928What this trial is testingBortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaWho this might be right forLymphoma University of Virginia 46
Early research (Phase 1)Study completedNCT01164709What this trial is testingNelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerWho this might be right forLeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more Swiss Cancer Institute 18